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Summary
PURPOSE: Craniopharyngioma-related hypothalamic
obesity is a devastating complication with limited data on
whether long-term follow-up should focus on problems
other than endocrine deficiencies and weight gain. The pri-
mary endpoint was the assessment of predictors of hy-
pothalamic obesity development; the secondary endpoint
was the assessment of functional outcome (endocrine de-
ficiencies, visual acuity) at long-term follow-up.
METHODS: This retrospective case-note study examined
craniopharyngioma patients with at least 2 years of follow-
up. Clinical, radiological and biochemical characteristics
were assessed at diagnosis, postoperatively, and at last
follow-up.
RESULTS: Thirty-two patients met the inclusion criteria.
Median follow-up period was 9.8 years (range 2.2–33
years). Longitudinal changes in body mass index (BMI)
were substantial (median ΔBMI/year was +0.48 kg/
m2/year, interquartile range 0.28–1.33). The prevalence
of patients with hypothalamic obesity had significantly in-
creased at last follow-up (45 vs 4%; p = 0.003). Long-term
pituitary deficiencies remained high. Diabetes insipidus
was common (66% vs 34%, p<0.001), with postoperative
diabetes insipidus but not hypothalamic involvement, be-
ing an independent predictor for hypothalamic obesity
(odds ratio 15.2, 95% confidence interval 1.3–174.8, p =
0.03). Osteodensitometry in two thirds of patients at last
follow-up revealed a pathological bone density in 53% of
those tested.
CONCLUSIONS: Rates of hypothalamic obesity and long-
term pituitary deficiencies are substantial, with postopera-
tive diabetes insipidus being a potential marker for hypo-
thalamic obesity development. Besides long-term monitor-
ing of endocrine deficiencies with consideration of osteo-
densitometry, early weight control programmes and con-
tinuing multidisciplinary care are mandatory in cranio-
pharyngioma patients.
Key words: craniopharyngioma, long-term outcome, obe-
sity, surgery, radiotherapy
Introduction
Craniopharyngiomas are rare intracranial lesions. Al-
though classified by the World Health Organization
(WHO) as grade I tumours, they recur quite often [1].
Morbidity can be significant as a result of mass effect
and tumour expansion into adjacent areas. Treatment has
been associated with a high likelihood of hypothalamic-
pituitary dysfunction [2]. In particular, excessive weight
gain in patients with hypothalamic involvement leading
to hypothalamic obesity has frequently been associated
with craniopharyngioma treatment [3]. Indications for rad-
ical resections (gross total resection), with lower recur-
rence rates but higher risks for morbidity, have to be bal-
anced against indications for subtotal resection to preserve
hypothalamic structures. Likewise, adjuvant radiotherapy
in this functional anatomic area is critical, especially in
younger patients [4]. Despite careful treatment planning,
craniopharyngioma patients frequently suffer from in-
creased rates of obesity postoperatively, even following
subtotal resection, which has serious consequences for
long-term morbidity and mortality [5]. Despite efforts to
provide treatment to reduce weight gain and thus cardio-
vascular diseases, hypothalamic obesity has been shown
to be less responsive to any weight control programmes
than common obesity [6]. There is currently limited data
on whether the long-term follow-up should be focused dif-
ferently, on specific problems other than endocrine defi-
ciencies and weight gain affecting late morbidity in these
patients.
The present study aimed at investigating the surgical long-
term outcome, seeking for predictors of hypothalamic obe-
sity development (primary endpoint). The secondary end-
point was the assessment of functional outcome (endocrine
deficiencies, visual acuity) at long-term follow-up.Correspondence:Emanuel Christ, MD, PhD,
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Subjects, material and methods
This study was approved by the Ethics Committee of Bern,
Switzerland, and was performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments.
Patient selection
In this retrospective case-note study, we evaluated the lon-
gitudinal medical data records of all patients who were
operated on for a histologically confirmed craniopharyn-
gioma. The minimum follow-up period required, in order
to document longitudinal changes, was 24 months. All pa-
tients were treated at our institution (single-centre study)
between 1980 and 2011. Patients’ demographic, en-
docrinological, neurological and ophthalmological charac-
teristics preoperatively, postoperatively and at last follow-
up were analysed.
Assessment of body mass index
Body mass index (BMI) z-scores, or BMI standard devia-
tion scores (SDS), were taken into account in patients with
childhood onset (<18 years of age) to calculate the rel-
ative weight adjustment according to the child’s age and
sex [7]. Patients with a z-score >2 SDS were considered
to be suffering from obesity. Standard BMI was calculated
for adult patients (adult-onset, at ≥18 years of age). There-
by, patients were categorised according to BMI as under-
weight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2),
overweight (25–29.9 kg/m2), or obese (>30 kg/m2).
Assessment of hypothalamic obesity and hypothalamic
involvement
Craniopharyngioma invasion of hypothalamic structures
(hypothalamic involvement) and/or treatment-related le-
sions of the hypothalamus were assessed by means of mag-
netic resonance imaging (MRI) of the brain [3]. Hypothal-
amic obesity was defined as significant obesity and post-
surgical weight gain in craniopharyngioma patients with
hypothalamic involvement or with postsurgical hypothala-
mic damage [8].
Endocrinological assessment
The diagnosis of hypothyroidism was based on the pres-
ence of low-normal thyroid stimulating hormone (TSH)
levels in parallel with low free thyroxine levels (FT4). Sec-
ondary adrenal insufficiency was assumed in the presence
of low fasting cortisol levels or an inappropriate response
of cortisol to adrenocorticotrophic hormone (ACTH), or
insulin-induced hypoglycaemia. A gonadotrophin defi-
ciency or central hypogonadism was considered when nor-
mal to low levels of gonadotrophins in the presence of low
serum testosterone/oestradiol concentrations were found in
adult-onset patients. In patients with childhood-onset tu-
mours, prepubertal gonadotrophin deficiency was defined
as the necessity for hormonal induction of puberty record-
ed during follow-up.
Growth hormone deficiency was defined as impaired
growth rate in children and low age-adjusted insulin-like
growth factor 1 levels (in children and adults) in parallel
with impaired function of three additional pituitary hor-
monal axes. Alternatively, an insulin tolerance test was
performed to diagnose growth hormone deficiency.
Visual assessment
Assessment of visual function included documentation of
visual acuity using the Snellen chart and visual field as-
sessment with the Goldmann manual perimeters.
Assessment of bone health status
Bone mineral density was assessed at last follow-up with
dual-energy X-ray absorptiometry (Hologic QDR 4500A®,
Bedford, MA, USA) of the femur, head and/or neck, tibia
and spine. According to the WHO classification, a T-score
≥−1 SD was regarded as normal, whereas a T-score of −1
to −2.5 SDs indicated osteopenia, and of <−2.5 SDs os-
teoporosis. Pathological bone density was considered to
be present if one of the aforementioned bones showed a
pathological T-score.
Assessment of recurrence
Craniopharyngioma recurrence was defined as the postop-
erative presence of a radiographically detectable tumour
after gross total resection and/or growth of the tumour seen
on subsequent radiological follow-up scans if a residual tu-
mour (i.e., subtotal resection) was present during the initial
postoperative imaging studies, as reported previously [9].
Statistical analysis
Data were analysed with IBM SPSS statistical software
Version 21.0 (IBM Corp., New York, NY, USA) and
GraphPad Prism Version 6.03 (GraphPad Software, San
Diego, CA, USA). Continuous variables were examined
for homogeneity of variance and are expressed as mean ±
standard error of the mean (SEM) unless otherwise not-
ed. For comparisons of means between two groups, Stu-
dent’s t-test was used for normally distributed data, and
the Mann–Whitney test for nonparametric data. Odds ra-
tios (ORs) and 95% confidence intervals (CIs) of indepen-
dent factors associated with hypothalamic obesity at the
last follow-up were analysed with univariate and multivari-
ate logistic regression. The variables tested were: age at
diagnosis, sex, hypothalamic involvement, histology (i.e.,
adamantinomatous), hyperprolactinaemia, and diabetes in-
sipidus. The multivariable logistic regression analysis in-
cluded all dependent risk factors in the univariable regres-
sion with a p-value ≤0.3 [10, 11]. Categorical variables
were compared by use of Pearson’s chi-square test or Fish-
er’s exact test, as appropriate. Differences were considered
significant when p ≤0.05 and reported p-values are two-
sided.
Results
Patients’ characteristics at baseline
Long-term follow-up (≥24 months) was recorded for 32
patients (16 female and 16 male) with histologically
proven craniopharyngioma. The median follow-up period
was 117 months (range 26–398 months). Hypothalamic in-
volvement was noted in 25% of all patients with cran-
iopharyngioma. Baseline characteristics were not signifi-
cantly different between patients with and without hypo-
thalamic involvement (table 1). The median age at diagno-
sis was 33.6 years (rang 3–70 years). Adynamia was noted
in 44% of all patients and headache in 46%, with no dif-
ferences between patients with and without hypothalamic
involvement. Visual acuity and visual field deficits were
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noted in 44% and 59% patients, respectively. Hormonal
deficiencies were present in the majority of patients, with
gonadotrophin (in 48% patients with adult onset vs 86%
patients with childhood onset) and secondary adrenal defi-
ciencies (in 31% of all patients) being the most frequent.
Tumour location and surgical/radio-oncological man-
agement
A solely intrasellar location was noted in two (9%) patients
who had craniopharyngioma without hypothalamic in-
volvement and in none of the patients with hypothalamic
involvement (p = 0.15). Occlusive hydrocephalus due to
tumour extension was noted in two (25%) patients with hy-
pothalamic involvement versus three (13%) patients with-
out hypothalamic involvement.
Gross total resection was attained in 26% of patients. None
of the patients were referred for proton therapy. Instead,
those assigned to adjuvant radiation therapy (i.e., patients
with subtotal resection) were treated with photon therapy.
Overall, nine (29%) patients received fractionated radio-
therapy and five (16%) patients LINAC-stereotactic ra-
diosurgery on. One patient received intracavitary irradia-
tion with locally implanted beta-emitting radioisotope yt-
trium-90 (90Y) silicate colloid. There was no difference in
the adjuvant therapy following craniopharyngioma treat-
ment between patients treated via the transcranial (45%) or
transnasal (33%) approaches (p = 0.99). There was no dif-
ference in the extent of craniopharyngioma resection be-
tween patients with or without hypothalamic involvement
(p = 0.99). Median cumulative doses of radiation were 54
Gy (range 9–56 Gy; on average 2 Gy in 25 fractions).
Histological results
Of the patients with a childhood-onset tumour, six (86%)
presented with an adamantinomatous and one (14%) with a
papillary craniopharyngioma. In the adult-onset cohort, 14
patients (58%) were diagnosed with an adamantinomatous
and 10 (42%) with a papillary craniopharyngioma. Histo-
logical diagnosis was not a predictor for long-term hypo-
thalamic obesity development (OR 1.4, 95% CI 0.3–6.4; p
= 0.71, table 2).
Postoperative complications
No perioperative mortality was recorded. Surgical compli-
cations included cerebrospinal fluid leak in two patients
(6%; one patient following the transcranial and one follow-
ing the transnasal approach), epileptic seizure in one (3%)
patient treated via the transcranial approach, peripheral fa-
cial nerve paralysis in one (3%) treated with transcranial








Female 10 (42) 6 (75) 16 (50)
Male 14 (58) 2 (25) 16 (50)
Age at diagnosis in years, median (range) 36.1 (6–70) 33.7 (2–61) 33.6 (3–70)
Tumour site
Intrasellar 2 (9) 0 (0) 2 (7)
Extrasellar 21 (91) 8 (100) 29 (93)
Hydrocephalus 3 (13) 2 (25) 5 (16)
Primary surgical approach
Transcranial 22 (92) 7 (88) 29 (91)
Transnasal 2 (8) 1 (12) 3 (9)
Extent of resection
Subtotal resection 17 (74) 6 (75) 23 (74)
Gross total resection 6 (26) 2 (25) 8 (26)
Adjuvant radiotherapy 11 (46) 4 (50) 15 (47)
Pathological finding
Adamantinomatous 16 (67) 5 (63) 21 (66)
Papillary 8 (25) 3 (9) 11 (34)
Clinical symptoms
Adynamia 9 (38) 5 (63) 14 (44)
Headache 9 (50) 2 (33) 11 (46)
Visual acuity deficits 11 (46) 3 (38) 14 (44)
Visual field deficits 15 (63) 5 (63) 20 (63)
Affected pituitary axes













Secondary adrenal insufficiency 7 (29) 3 (38) 10 (32)
Secondary hypothyroidism 6 (25) 2 (25) 8 (25)
Hyperprolactinaemia 5 (21) 3 (38) 8 (25)
Diabetes insipidus 3 (13) 1 (13) 4 (13)
Follow-up in years, median (range) 102.5 (26–398) 157.5 (42–272) 117 (26–398)
GH = growth hormone; HI = hypothalamic involvement
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surgery, and anosmia in three (9%) patients treated with
transcranial surgery.
Weight control
Changes in weight gain and the BMI categories (normal,
overweight, obese) are depicted in fig. 1. A significant in-
crease in BMI was recorded at long-term follow-up (from
23.1 ± 4.9 to 28.4 ± 4.9 kg/m2; p <0.001, fig. 1A). There
was, furthermore, a significant increase in the BMI of pa-
tients with hypothalamic involvement (28.9 vs 23.5 kg/m2
at baseline, p <0.001). At diagnosis, 14% of patients with
a childhood-onset craniopharyngioma presented with a z-
score >2 SDS. Of the patients with an adult-onset cran-
iopharyngioma, 43% were overweight and 3% obese. The
proportion of patients with a normal BMI was significant-
ly higher at baseline (53%) compared with last follow-up
(24%; p = 0.03); the prevalence of hypothalamic obesity
had significantly increased at last follow-up (45 vs 4%; p =
0.003, fig. 1B). At long-term follow-up, overweight (BMI
25–30 kg/m2) was noted in 9 patients (31%) and obesity
(BMI ≥ 30 kg/m2) in 13 (45%). Severe obesity (BMI >35
kg/m2) was noted in two (6%) patients.
The median ΔBMI/year was +0.48 kg/m2/year, interquar-
tile range (IQR) 0.28–1.33 kg/m2/year. There was no dif-
ference in median ΔBMI/year between gross total and
subtotal resection (+0.46 kg/m2/year, IQR 0.25–1.43 vs
+0.53 kg/m2/year, IQR 0.31–1.2; p = 0.31).
In patients treated with adjuvant radiotherapy, the median
ΔBMI/year was +0.73 kg/m2/year (IQR 0.37–3.14) com-
pared with +0.45 kg/m2/year (IQR 0.18–0.96) in those who
did not undergo radiotherapy (p = 0.12).
Visual outcome
Visual field and acuity deficits improved after surgery,
although not statistically significantly (table 3). Eighteen
(56%) patients with craniopharyngioma showed visual
field deficits at diagnosis, and one of them improved fol-
lowing surgery. In contrast, 14 (44%) patients showed vi-
sual acuity deficits at baseline, and 9 (28%) of them
showed persisting deficits at last follow-up (p = 0.29).
Endocrinological outcome
Hormonal deficiencies at diagnosis and last follow-up are
summarised in table 3. Long-term deficits were signifi-
cantly increased compared with preoperative values, no-
tably in the growth hormone axis (63 vs 9%, p <0.001),
ACTH axis (84 vs 31%, p <0.001), TSH axis (81 vs 25%,
p <0.001) and diabetes insipidus (66% vs 13%, p <0.001),
but not hyperprolactinaemia (41 vs 25%, p = 0.29). The cu-
mulative pituitary dysfunctions – the mean sum score (%)
of hormonal axes deficiencies – are depicted in figure 2. It
reflects the sum of hormonal axes deficits (%), including
growth hormone and secondary adrenal insufficiency, hy-
pothyroidism, gonadotrophin deficiency or central hypog-
onadism, and hyperprolactinaemia preoperatively, postop-
eratively (3 months later) and at last follow-up. There was
a significant increase in cumulative pituitary axes deficits
compared with preoperative values (p <0.001, fig. 2A).
Table 2: Predictors for long-term hypothalamic obesity development.





Age 1.0 (0.9–1.0) 0.29 1.0 (0.9–1.1) 0.34
Follow-up period 1.0 (0.9–1.0) 0.73
Sex (i.e., women) 2.7 (0.6–12.0) 0.20 5.3 (0.4–67.6) 0.20
Hypothalamic involvement 2.7 (0.5–14.5) 0.25 3.6 (0.5–26.6) 0.22
GTR 1.3 (0.3–6.5) 0.78
Adjuvant radiotherapy 1.5 (0.3–6.5) 0.59
Histology (adamantinomatous) 1.4 (0.3–6.4) 0.71
Postoperative hyperprolactinaemia 2.9 (0.6–13.5) 0.18 3.2 (0.4–22.8) 0.26
Postoperative diabetes insipidus 5.1 (1.0–26.7) 0.06 20.5 (1.5–284.2) 0.02
BMI = body mass index; CI = confidence interval; GTR= gross total resection; HO = hypothalamic obesity: OR = odds ratio
Figure 1: Stacked bar chart of patients’ BMI at baseline and long-term follow-up and changes in BMI over the study period. (A) There was a
significant increase in patients’ BMI at long-term follow-up (from 23.1 ± 4.9 to 28.4 ± 4.9 kg/m2; p < 0.001). (B) At baseline, there was a signifi-
cantly higher prevalence of patients with a normal BMI (53%) than at last follow-up (24%; p = 0.03). In contrast, at last follow-up, the preva-
lence of hypothalamic obesity significantly increased (45 vs 4%; p = 0.003).
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Long-term deficits of hormonal axes were not significantly
different from postoperative deficiencies (p = 0.62). Long-
term endocrine deficiencies remained high and were more
severe in male than female patients (p = 0.05, fig. 2B).
Bone health
At the last follow-up, osteodensitometry was performed in
19 patients (59%), revealing a pathological bone density in
53% of them, namely in one 39-year-old patient who had
had childhood-onset craniopharyngioma and in 50% of the
patients with adult-onset craniopharyngioma, at a median
age of 52 years (range 30–65 years).
Recurrences, tumour growth and disability
None of the craniopharyngiomas treated with gross total
resection relapsed or grew, whereas in seven (30%) pa-
tients with subtotal resection the tumour recurred (p =
0.15). There was no significant difference in the recurrence
rate according to the surgical approach: six (21%) patients
undergoing transcranial surgery versus one patient (33%)
undergoing transnasal surgery (p = 0.54). At last follow-
up, four (21%) women and one (5%) man were claiming
disability insurance.
Discussion
The main findings of this study can be summarised as fol-
lows. After a median follow-up period of 10 years: (1)
a high prevalence of hypothalamic obesity was record-
ed, with postoperative diabetes insipidus being a potential
marker for hypothalamic obesity development; (2) long-
term endocrine deficiencies remained significantly high;
(3) visual deficits improved, although not significantly;
and (4) osteodensitometry revealed impaired bone density
in a substantial number of patients.
Hypothalamic obesity
We observed a significant increase in patients’ BMI at
long-term follow-up, particularly in those with hypothal-
amic involvement. An increase in the percentage of pa-
tients suffering from hypothalamic obesity over time is
an established phenomenon [12]. An increase in patients’
BMI over the long term might partly be related to the nor-
mal age-associated increase in body weight [13], but obe-
sity has been shown to be the most common manifesta-
tion of hypothalamic damage, with hypothalamic involve-
ment, in turn, being a long-term predictor for hypothalamic
obesity development in patients with craniopharyngiomas
[14]. Although early preventive measures for weight con-
trol have been shown to be beneficial, they are difficult
to implement [15]. A recent systematic review and meta-
analysis of craniopharyngioma patients with obesity
showed that bariatric surgery induced weight loss at 1-year
follow-up, but the impact was far less significant than in
patients without craniopharyngiomas [15], corroborating







Visual field deficits 19 (59) 18 (56) 0.99
Visual acuity deficits 14 (44) 9 (28) 0.29
Affected pituitary axes
Growth hormone insufficiency 3 (9) 20 (63) <0.001
Gonadotropin deficiency 13 (41) 28 (88) <0.001
Secondary adrenal insufficiency 10 (31) 27 (84) <0.001
Secondary hypothyroidism 8 (25) 26 (81) <0.001
Hyperprolactinaemia 8 (25) 13 (41) 0.29
Diabetes insipidus 4 (13) 21 (66) <0.001
Figure 2: Cumulative pituitary deficiencies over the study period. (A) There was a significant increase in the cumulative pituitary axes deficits
compared with baseline (p <0.001) or postoperative values (p <0.001). Long-term deficits in hormonal axes were not significantly different from
postoperative deficiencies (p = 0.62). (B) Long-term endocrine deficiencies remained high and were more severe in male than female patients
(p = 0.05)ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001
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the finding that obesity associated with craniopharyngioma
is different from primary obesity.
Interestingly, weight gain did not differ between patients
treated with subtotal or gross total resection, contrary to
previous findings indicating that a more conservative ap-
proach reduces the risk of hypothalamic obesity [16]. The
relatively low number of patients in our study may account
for these controversial findings. Conversely, in patients
treated with adjuvant radiotherapy, the average weight gain
was higher than in those not treated with radiotherapy. This
is in accordance with previous reports that additional high-
dose radiotherapy (51–72 Gy) was a risk factor for hy-
pothalamic obesity [17]. The relatively small number of
patients studied may explain the lack of statistical signifi-
cance.
The postoperative occurrence of diabetes insipidus was a
significant and independent risk factor for long-term de-
velopment of hypothalamic obesity, but not hypothalamic
involvement. This is an interesting and intriguing finding,
which was recently reported by Roth et al. [3]. It can be
speculated that diabetes insipidus is a marker for the sever-
ity of disease. Given the high prevalence, with about half
of all patients (45%) developing hypothalamic obesity at
last follow-up (in line with prior studies [18]), the post-
operative presence of diabetes insipidus might become an
easy and inexpensive marker to assess patients’ risk for hy-
pothalamic obesity development. This in turn would iden-
tify patients for whom closer monitoring and potentially
aggressive intervention aiming at weight control is war-
ranted.
Endocrine deficiencies
No reversal of pre-existing pituitary hormone deficiencies
was noted, which is consistent with previous findings [19].
Van Effenterre noted that most patients with craniopharyn-
gioma presented with insufficient pituitary axes over the
study period [20]. Persistence of hypopituitarism might be
due to irreversible tumour damage of the hypothalamic-pi-
tuitary system in cases of surrounding tissue infiltration, or
a consequence of surgery, radiation therapy or tumour re-
currence. As shown by Tomlinson et al., patients with hy-
popituitarism have an excess mortality, with craniopharyn-
giomas an independent risk factor [21]. However, specific
endocrine axis deficiencies, with the exception of untreat-
ed gonadotrophin deficiency, did not appreciably worsen
the prognosis [21]. In our cohort, the extent of the surgical
approach (subtotal or gross total resection) did not result in
different outcomes with regard to hormonal deficiencies.
Although hypopituitarism is almost universally reported
with any approach for treating craniopharyngiomas, a
transnasal approach may lead to less morbidity and hor-
monal deficiency in selected cases [22].
Visual deficits
Preoperative and long-term visual acuity and visual field
deficits improved following treatment, although not sig-
nificantly. This is in contrast to a report by Lee et al.,
in which preoperative visual field deficits were associated
with worse postoperative visual deficits [23]. Recently,
Drimtzias and co-workers assessed the natural history and
visual outcome of 20 patients with craniopharyngiomas,
predominantly treated with subtotal resection. In their
study, preoperative visual field deficits and type of surgery
were not prognostic indicators for postoperative visual
acuity and visual field deficits. Interestingly, type of
surgery and preoperative visual field deficits were not as-
sociated with craniopharyngioma recurrence, so that mon-
itoring for recurrence of craniopharyngioma with MRI
rather than by means of visual field assessment was recom-
mended [24].
Bone health status
Fifty-three percent of patients who underwent osteoden-
sitometry had a pathological bone density at last follow-
up. This may reflect normal age-related bone loss. How-
ever, tumour-induced hypogonadism has been shown to
contribute more than patients’ age to the high prevalence
of pathological bone density [25]. In adults with childhood
onset craniopharyngiomas, bone mineral density was low-
er than in healthy control subjects and discontinuation of
growth hormone therapy before peak bone mass was
achieved is a potential cause for this phenomenon [26].
Patients with hypopituitarism, in particular those with go-
nadotrophin and growth hormone deficiency, suffer from
early bone loss because of their inability to build up their
peak bone mass in the first three decades of life [27]. Over-
weight may protect against bone loss, probably through the
increase in fat mass with the action of augmented leptin
levels and peripheral conversion of androgens to oestra-
diol [28]. However, it is conceivable that hypothalamic
structures might become insensitive, in particular to the in-
creased levels of endogenous leptin in craniopharyngioma
patients [29], with leptin resistance in adolescents being
negatively correlated to bone mineral density [30]. The re-
lationship between leptin and bone mineral density is com-
plex, with different effects depending on whether central or
peripheral mechanisms are operating [31].
Extent of tumour resection and recurrence rate
None of the craniopharyngiomas recurred after gross total
resection compared with 17% following subtotal resection.
In addition, recurrence and growth rate were independent
of the surgical approach (transnasal vs transcranial). Cur-
rently, the optimal surgical approach for craniopharyn-
giomas is still a matter of debate. Whereas some authors
suggest gross total resection only if hypothalamic morbid-
ity is acceptably low [32], others support a primary subto-
tal resection accompanied by radiotherapy [33]. Excellent
rates of disease control with a favourable functional out-
come have been reported when radical resection was at-
tempted using a standard or extended transnasal approach
[22]. However, even at highly experienced centres, gross
total resection can result in hypothalamic disorders with
significant morbidities. In our cohort, adjuvant radiothera-
py followed subtotal resection in 14 (61%) patients. As a
result of progress made in supportive care, radiation ther-
apy and hormone replacement, less invasive approaches
have resulted in an improved quality of life [34]. This has
led to less radical surgical approaches, with reduced rates
of hypothalamic lesions and thus reduced hypothalamic
obesity development, being proposed [35]. In the case of
subtotal resection of craniopharyngiomas, close follow-up
in a referral centre remains indispensable so that adjuvant
fractionated radiotherapy, stereotactic radiosurgery or re-
operation can be promptly instigated. As mentioned above,
monitoring for recurrence of craniopharyngiomas by use of
Original article Swiss Med Wkly. 2018;148:w14521
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 8
MRI rather than by visual acuity or field assessment was
recommended owing to poor correlation of recurrence with
the latter [24]. Markers of recurrence have been difficult
to identify, with symptoms of intracranial hypertension be-
ing the most promising predictor [36]. The recent detec-
tion of frequent and clonal mutations in β-catenin (cad-
herin-associated protein; CTNNB1) in adamantinomatous
craniopharyngiomas and the B-RAF proto-oncogene ser-
ine/threonine-protein kinase (BRAF) in papillary cranio-
pharyngiomas show promise for testing molecularly guid-
ed therapeutics in the treatment of these neoplasms [37].
In conclusion, rates of hypothalamic obesity and long-
term endocrine deficiencies in patients with craniopharyn-
giomas are substantial, with postoperative diabetes in-
sipidus being a potential marker for hypothalamic obesity
development. Besides long-term monitoring of endocrine
deficiencies, with consideration of osteodensitometry, ear-
ly weight control programmes and continuing multidisci-
plinary care are mandatory in all patients suffering from
this chronic disease.
Study limitations
This study suffers from the limitations of any retrospective
study, the small number of patients, and the single-centre
design. Furthermore, this study spans a mean observation
period of ≥10 years during which there have been signif-
icant advances in neurosurgical techniques and materials,
perioperative care and hormone replacement therapy, ra-
diotherapy and radiosurgery, which may affect outcome.
The number of patients is relatively small and assessment
of multiple independent predictors for hypothalamic obe-
sity development using multiple logistic regressions was
thus limited. Statistical uncertainty in this small sample
size precluded us from discriminating outcome parameters
between childhood- and adult-onset patients. Likewise, the
small sample size precluded us from performing any sub-
analysis in those treated with radiosurgery only. The radi-
ological assessment of hypothalamic involvement, includ-
ing the degree of surgical resection (gross total or subtotal
resection), was not subjected to a blinded review by two
independent specialists, but rather was based on the report-
ed findings recorded during the observational period.
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